New Product line for Clinical Diagnostics

Share This Post

ProGnosis Biotech made the first step in the Clinical Diagnostics field with Rapid Test Ag 2019 n-CoV and is now is lauching the new additions to its catalog.

A whole new line of Clinical Diagnostics is available to offer solution for the ongoing battle against viruses. Our new Rapid Tests can detect, with high specificity and sensitivity, the presence of specific viral antigens, indicative of
infections.

The new products include:

• Combo Rapid Test that differentiates between SARS-CoV-2 virus (COVID-19) and the Flu (influenza A&B).

• Flu Rapid Test that differentiates between Influenza A and Influenza B.

• Rapid Test that detects Adenoviruses that cause respiratory illness

• Rapid Test that detects the Respiratory Syncytial Virus (RSV).

Learn more about them by clicking here

More To Explore

RAFA 2022

The 10th International Symposium on Recent Advances in Food Analysis RAFA 2022, took place in Prague from the 6th until the 9th of September.  ProGnosis

ASM-MYCOTOX 2022

On the 4th of September ProGnosis Biotech ventured in South Africa for the 3rd African Symposium on Mycotoxicology, as a Gold Sponsor.  The 4-day Symposium,